JY
DMRA

Jeff Yass’s Damora Therapeutics DMRA Stock Holding History

Jeff Yass’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,476
Closed -$93K – 12354
2023
Q2 		$93K Buy
+1,476
New +$80.4K ﹤0.01% 11000
2023
Q1 		– Sell
-412
Closed -$11.8K – 12912
2022
Q4 		$11.8K Sell
412
-756
-65% -$31.4K ﹤0.01% 11906
2022
Q3 		$55K Buy
+1,168
New +$59.2K ﹤0.01% 12133

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Jeff Yass's DMRA Position: Q2 2026 in Review

Jeff Yass increased its Damora Therapeutics (DMRA) stake by 23% in Q2 2026, buying an estimated $54.2K and bringing the position to 12,009 shares worth $312K. The position accounts for ﹤0.01% of the portfolio, ranked #10959.

Jeff Yass first reported a position in DMRA in Q4 2021 and has held it in 11 quarters since. 103 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

  • Jeff Yass held 12,009 shares of Damora Therapeutics worth $312K as of Q2 2026.
  • Jeff Yass bought 2,239 Damora Therapeutics shares in Q2 2026, an estimated $54.2K.
  • Damora Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #10959 holding.
  • Jeff Yass first reported a position in Damora Therapeutics in Q4 2021 and has held it in 11 quarters since.
  • 103 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.